*Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 4, 2024 (the "**Prospectus**") issued by QuantumPharm Inc. (the "**Company**").*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) in the United States to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to Rule 144A or another available exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.

XtalPi
晶 泰 科 技

QuantumPharm Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of QuantumPharm Inc. (the "**Company**") dated July 7, 2024 in relation to the partial exercise of the over-allotment option, stabilizing actions and end of stabilization period (the "**Announcement**"). Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to clarify that, due to inadvertent clerical error, the additional net proceeds of "approximately HK$47.31 million" in the Chinese version of the Announcement should have been "approximately HK$45.82 million" as disclosed in the English version of the same Announcement.

Save as disclosed above, all contents within the Chinese and English versions of the Announcement remain unaffected and unchanged.

By order of the Board
QuantumPharm Inc.
Dr. Wen Shuhao
Chairman of the Board and Executive Director

Hong Kong, July 8, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, Dr. Gu Cuiping as a non-executive Director, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.